Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome
Cancer · 2024
DOI: 10.1002/cncr.35251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Ashley Dinh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Triazoles, Myelodysplastic Syndromes, Pyridines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Ivosidenib is primarily metabolized by CYP3A4; however, it induces CYP450 isozymes, including CYP3A4 and CYP2C9, whereas it inhibits drug transporters, including P‐glycoprotein. Patients with acute myeloid leukemia are at risk of invasive fungal infections, and therefore posaconazole and voriconazole are commonly used in this population. Voriconazole is a substrate of CYP2C9, CYP2C19, and CYP3A4; therefore, concomitant ivosidenib may result in decreased serum concentrations. Although posaconazole is a substrate of P‐glycoprotein, it is metabolized primarily via UDP glucuronidation; thus, the impact of ivosidenib on posaconazole exposure is unknown.
Methods
Patients treated with ivosidenib and concomitant triazole with at least one serum trough level were included. Subtherapeutic levels were defined as posaconazole
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Ashley Dinh, Hagop M Kantarjian, Courtney D DiNardo, Caitlin R Rausch
Zitieren
APA
Dinh, A., Savoy, J. M., Kontoyiannis, D. P., Takahashi, K., Issa, G. C., Kantarjian, H. M., DiNardo, C. D., & Rausch, C. R. (2024). Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. https://doi.org/10.1002/cncr.35251
Vancouver
Dinh A, Savoy JM, Kontoyiannis DP, Takahashi K, Issa GC, Kantarjian HM, et al. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2024. doi:10.1002/cncr.35251
BibTeX
@article{Dinh2024,
author = {Dinh, Ashley and Savoy, J Michael and Kontoyiannis, Dimitrios P and Takahashi, Koichi and Issa, Ghayas C and Kantarjian, Hagop M and DiNardo, Courtney D and Rausch, Caitlin R},
title = {Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35251}
}
EUVIMED